Sanofi announced on Tuesday a simplification of its contractual agreements with AstraZeneca and Sobi, so that the French group will now have full commercial control of nirsevimab, a treatment project against RSV, in the United States.
At the end of these new contracts, Sanofi will terminate its participation agreement with the Swedish laboratory Sobi, while updating its existing partnership with AstraZeneca.
The modification of the collaboration with AstraZeneca will give Sanofi full commercial control of nirsevimab in the United States, without questioning the agreements concluded for territories outside the American market.
Nirsevimab, or Beyfortus by its trade name, is an investigational, long-acting antibody designed to protect infants against RSV infections from birth through their first viral season with a single dose.
Jointly developed by Sanofi and AstraZeneca, the drug is expected to hit the market in time for the 2023/24 respiratory syncytial virus season.
In its press release, Sanofi points out that it has simultaneously entered into a direct royalty agreement with Sobi in order to share a portion of the net sales of nirsevimab in the United States.
Listed on the Paris Stock Exchange, the Sanofi title fell by 0.6% Tuesday morning on the Paris Stock Exchange, in a Parisian market in sharp progression (+0.6%).
Yesterday, Sanofi announced the withdrawal and resubmission of the Hart-Scott-Rodino pre-merger notification and reporting form, as well as the extension of its tender offer for Provention.
The goal is to provide the Federal Trade Commission (FTC) additional time to review the proposed merger.
The statutory waiting period will expire on April 25, while the transaction is expected to close in the second quarter.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
